Evaluating the Safety and Immunogenicity of MTBVAC

This study (HVTN 605) is testing the safety and immune response to MTBVAC — an experimental tuberculosis (TB) vaccine — in healthy adults and people living with HIV. TB is a leading infectious disease killer worldwide, and MTBVAC is being tested as a potentially more effective replacement for the current BCG vaccine. **You may be eligible if...** - You are between 12 and 55 years old and received the BCG vaccine as an infant - You are in good general health based on exams and lab tests - You are HIV-negative with a low likelihood of acquiring HIV, OR you are HIV-positive on stable treatment with an undetectable viral load and an adequate immune cell count - You are willing to use contraception if there is a chance of pregnancy **You may NOT be eligible if...** - You weigh less than 40 kg - You have been recently exposed to TB, have a history of active TB, or are showing signs of active TB - You are pregnant or breastfeeding - You have an autoimmune disease, uncontrolled diabetes, poorly controlled asthma, or a bleeding disorder - You received certain vaccines, blood products, or immune-suppressing drugs recently Talk to your doctor to see if this trial is right for you.